Intravenous delivery of the cyclic STAT3 decoy has been shown to potently inhibit the growth of both non-small cell lung cancer and head and neck cancer xenograft tumors [105,109,110]. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.